Rebif Rebidose User Reviews & Ratings
Rebif Rebidose has an average rating of 7.8 out of 10 from a total of 4 reviews on Drugs.com. 75% of reviewers reported a positive experience, while 0% reported a negative experience.
Condition | Avg. Rating | Reviews | Compare |
---|---|---|---|
Multiple Sclerosis | 4 reviews for Multiple Sclerosis | 102 medications |
- jim...
- January 24, 2018
For Multiple Sclerosis "I have been diagnosed since I was 32 years old, I am now 59 years old. I started on Avonex, which lasted a couple of years before I went on Rebif 44 mcg and have been fairly stable. I certainly look really healthy, but the nature of my work was long hours and physically and mentally stressful. Rebif must have helped, but I also relied on pain meds and muscle relaxers, or I would have never survived."
- Gun...
- December 23, 2015
For Multiple Sclerosis "Easy to use, no side effects experienced as opposed to interferon beta medication. Good support program and co-pay assistance. Has lessened progression."
- Goo...
- Taken for 10 years or more
- April 1, 2017
For Multiple Sclerosis "Have been on it for 10 years and have had some activity but no major episodes. Downside: long-term anemia and resulted in avascular necrosis and had to have my hip replaced."
Are you taking this medicine?
Your review helps others make informed decisions.More about Rebif Rebidose (interferon beta-1a)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: interferons
- En español
Patient resources
Other brands
Avonex, Rebif, Avonex Pen, Avonex Prefilled Syringe
For Multiple Sclerosis "I had no issues the first 6 months on Rebif. Medicated before each injection, so didn't get the flu-like symptoms. However, things changed starting at month 6. Started getting red, itchy spots at the injection sites. Also got cellulitis 4 times. And to top it off, got 1 new lesion. Still on it, but in the process of switching to Tysabri. 2 lesions did shrink in size though."